On Tuesday, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was -5.23% drop from the session before settling in for the closing price of $19.90. A 52-week range for ARWR has been $17.05 – $36.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -2.87% over the last five years. When this article was written, the company’s average yearly earnings per share was at 46.57%. With a float of $116.97 million, this company’s outstanding shares have now reached $125.57 million.
The firm has a total of 609 workers. Let’s measure their productivity. In terms of profitability, gross margin is -272.28%, operating margin of -25037.88%, and the pretax margin is -25870.12%.
Arrowhead Pharmaceuticals Inc (ARWR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arrowhead Pharmaceuticals Inc stocks. The insider ownership of Arrowhead Pharmaceuticals Inc is 7.24%, while institutional ownership is 77.04%. The most recent insider transaction that took place on Jan 23 ’25, was worth 20,139. In this transaction Director of this company sold 959 shares at a rate of $21.00, taking the stock ownership to the 35,781 shares. Before that another transaction happened on Jan 23 ’25, when Company’s Director proposed sale 959 for $20.97, making the entire transaction worth $20,108.
Arrowhead Pharmaceuticals Inc (ARWR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 46.57% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
You can see what Arrowhead Pharmaceuticals Inc (ARWR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 951.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.15, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -3.74 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Analysing the last 5-days average volume posted by the [Arrowhead Pharmaceuticals Inc, ARWR], we can find that recorded value of 1.24 million was lower than the volume posted last year of 2.12 million. As of the previous 9 days, the stock’s Stochastic %D was 58.77%. Additionally, its Average True Range was 1.12.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 17.59%, which indicates a significant decrease from 30.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.82% in the past 14 days, which was lower than the 67.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.01, while its 200-day Moving Average is $22.43. Now, the first resistance to watch is $19.64. This is followed by the second major resistance level at $20.42. The third major resistance level sits at $20.94. If the price goes on to break the first support level at $18.33, it is likely to go to the next support level at $17.81. Now, if the price goes above the second support level, the third support stands at $17.03.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
There are 126,098K outstanding shares of the company, which has a market capitalization of 2.38 billion. As of now, sales total 3,550 K while income totals -599,490 K. Its latest quarter income was 2,500 K while its last quarter net income were -173,090 K.
